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1. Introduction
  Cytomegalovirus (CMV) reactivation in apparently 
immunocompetent individuals with critical illness is 
becoming an area of emerging clinical significance[1,2]. 
CMV reactivation is associated with a significant 81% 
higher mortality rate than that in critically ill patients 
without active CMV infection and also higher morbidity in 
terms of increased duration of ICU stay, longer duration 
of mechanical ventilation and higher rates of nosocomial 
infection[1]. However, severe CMV as initial presentation 
mimicking dengue infection is rare. We recently came 
across seven cases with positive CMV serology at intensive 
care unit (ICU) admission, of which initial three patients 
succumbed. Hence early administration of ganciclovir was 
decided in subsequent patients. One patient left the hospital 
against medical advice. Here we describe three cases of 
severe CMV who were successfully treated with intravenous 
ganciclovir. This drug was well tolerated and progressive 
improvement of organ function was observed after antiviral 
therapy. 
 
2.  Case report
2.1. Case 1
  A 20 year old female patient, primigravida, 36 weeks 
pregnant, presented with high grade fever associated with 
chills and rigors, progressively increasing shortness of 
breath for 1 week. Her antenatal period was otherwise 
uneventful and there were no associated co-morbid 
conditions. On admission to ICU she was febrile (101.5 oF),
and tachypnic (respiratory rate=35/min). Preliminary 
investigations revealed low platelet count (88 000/mm3) and 
elevated liver enzymes. (SGPT-88 IU/L, SGOT-130 IU/L) and 
negative for malaria parasite. Chest radiograph revealed 
bilateral infiltrates. Patient was intubated and mechanically 
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ventilated in view of deteriorating oxygen saturation and 
low PaO2 on ABG. Ultrasound revealed a single live fetus 
with tachycardia (FHR=180/min). Obstetrician's opinion was 
sought and emergency cesarian section was done. A 1.8 kg 
female child with APGAR score 8/10 delivered and admitted 
to neonatal ICU. Detailed infectious diseases work-up 
revealed negative dengue NS1 Ag, Ig M, Ig G, leptospira Ig 
M. CMV IgM (ELISA method and MEIA by automated system 
Abbott Axysm) was positive. She started on IV gancyclovir 
in addition to IV antibiotics. Patient became afebrile. Upon 
improvement in chest X-ray and ABG she was weaned off 
the ventilator and extubated on 3rd post operative day. 
Hepatopathy was resolved. Subsequently she was shifted to 
ward and discharged a week later. 
 
2.2. Case 2
  A 45 year old female patient, nil comorbids, presented 
with high grade fever, with chills and shortness of breath. 
Initial ABG revealed severe hypoxemia on 8 L oxygen with 
Hudson mask (PaO2 50 mmHg). She was connected to BiPAP, 
nonivasive ventilator with oronasal mask. Biochemical 
investigations were unremarkable except for raised liver 
enzymes (SGOT 132 IU/L and SGPT 122 IU/L. CRP 302 mg/L. 
She had mild thrombocytopaenia (platelet 1.3 lakhs/mm3). 
Dengue, malaria, leptospira, typhoid, hepatitis serology were 
negative. CMV IgM was positive on day 3 of ICU admission. 
CT chest revealed bilateral airspace consolidation. Apart 
from antibiotics, she started on IV gancyclovir. After four 
days of antiviral therapy she was improved clinically. 
CRP decreased to 28 mg/L. She was shifted to ward and 
discharged subsequently. Gancyclovir was continued for
2 weeks.
2.3. Case 3
  19 year old male patient, with no prior comorbidity, 
presented with fever chills and rigors, altered consciousness, 
GCS 6. Mechanical ventilation was instituted. Liver enzymes 
and serum bilurubin was very high (SGOT 553 IU/L, SGPT 
1 772 IU/L, total bilurubin 11.8 mg/dL, conjugated 9.6 mg/dL 
and unconjugated 2.2 mg/dL) INR 2.2 s. X ray chest revealed 
bilateral patchy consolidation. Platelets count 1.6 lakhs/
mm3. Anti HAV and CMV IgM were positive. IV ganciclovir 
was started. The liver enzymes and the INR decreased 
eventually but bilirubin remained high and the patient 
could be extubated on day 5 and shifted out of ICU on day 7. 
Ganciclovir was given for 8 d. 
  Three out of initial seven patients died. All of them 
presented with thrombocytopenia, hepatic dysfunction, 
breathlessness, fever with chills and rigors. One patient 
was 17 year old male and the second one was 30 year old 
female and the third one was 27 year old female patients. 
In our medical ICU, we don't routinely screen for CMV on 
admission. As all these young otherwise immunocompetent 
patients tested negative for dengue, malaria, hepatitis, 
they were screened for CMV serology as add-on laboratory 
investigations. All the three patients succumbed before 
laboratory results became available (within 2nd day of ICU 
admission) and antiviral therapy could not be instituted. 
3. Discussion
  CMV infection is among the most common opportunistic 
infections in immunocompromised patients such as solid 
organ transplant recipients, patients receiving chemotherapy 
for cancer or patients with human immunodeficiency 
virus. Even the critically ill patients considered non-
immunocompromised, once admitted to the intensive care 
units, present features consistent with immunosupression, 
such as reactivation of latent viral infections, such as CMV[3]. 
CMV reactivation occurs in critically sick patients admitted 
in ICUs and the reported prevalence ranges from 0%-35% 
in different studies[4]. According to a systematic review 
by Osawa et al, potential risk factors for CMV reactivation 
included sepsis, requirement of mechanical ventilation, and 
transfusions. Prolonged mechanical ventilation (21 to 39 d vs. 
13 to 24 d) and duration of ICU stay (33 to 69 d vs. 22 to 48 d) 
correlated significantly with a higher risk of CMV infection[5]. 
Mortality rates in patients with CMV infection were higher 
in some but not all studies[5]. Heininger et al assessed 
the clinical outcomes of nonimmunosuppressed critically 
ill patients with severe sepsis who had CMV reactivation 
They found that intensive care unit stay, hospital stay and 
mechanical ventilation were all significantly prolonged in 
patients with CMV reactivation compared with those without 
reactivation, but the mortality rate was not different between 
groups[6]. The inclusion of an imbalanced proportion of 
patients with active cytomegalovirus infection may severely 
compromise the reliability of outcome results of severe 
sepsis trials independent of their design. Even randomized 
trials could have a much higher probability of false-negative 
rates for a new therapy than designed. Future severe sepsis 
trials should consider including active cytomegalovirus 
infection as a prospective covariate[7].
  The mechanism(s) underlying the observed association 
between CMV and adverse clinical outcomes are not 
completely understood. Because most people are infected 
with this ubiquitous virus by adulthood, confirming 
pathogenicity has now become a clinical priority[8]. 
Cytomegalovirus-mediated immunosuppression leading to 
an increased risk of secondary infections and CMV-mediated 
lung injury are the most plausible mechanisms in these 
clinical settings[9]. In the pathogenesis immunodysfunction 
and imbalance in immunomodulatory mediators principally 
tumor necrosis factor and nuclear factor 毷B are involved[2]. 
However, we encountered patients who presented with high 
grade fever, thrombocytopenia, deranged liver enzymes 
and progressive shortness of breath requiring mechanical 
ventilation and had positive CMV serology within day 1 of 
ICU admission.
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  Clinical spectrum of CMV disease ranges from a mild 
mononucleosis-like syndrome to very severe multivisceral 
involvement[4]. All types of visceral involvement eg. 
interstitial pneumonitis, hematological disorders, hepatitis 
and several others have been observed in critically ill 
patients admitted in ICUs[4]. CMV can virtually affect any 
organ even in otherwise immunocompetent individuals and 
thus should be kept in the differential diagnosis of critically 
ill patients admitted in ICUs with unexplained fever and 
multi-system involvement. 
  Diagnosis of CMV infection in such critically ill but 
immunocompetent cases is another area of controversy and 
there are no uniform guidelines available. The conventional 
methods for the diagnosis of CMV infection/disease are viral 
isolation by viral culture, serology which includes CMV 
specific antigen and IgM antibody detection, and molecular 
method for detection of viral DNA from blood and other 
clinical specimens[4]. Viral isolation done by either tissue 
culture or shell vial culture is the most specific diagnostic 
test and until now is regarded as the gold standard, but it is 
availability is restricted to reference research laboratories. 
We limited our diagnostic testing to CMV serology 
and accept this limitation. Real time PCR assays have 
substituted other diagnostic methods for CMV reactivation/
invasive disease, as it is more sensitive and specific for 
early detection of CMV disease, is helpful in monitoring the 
virus load and is a more reliable marker for monitoring the 
clearance of the virus from blood[10-13]. 
  Another debatable area is issues of treating CMV infection 
in cases of immunocompetent individuals[4]. In both solid 
organ and haematopoietic stem cell transplant recipients, 
clearance of viraemia is shown to be helpful in guiding 
the duration of therapy[14], however very few studies 
have addressed this issue in critically ill patients with 
CMV reactivation[8]. Out of the seven patients with CMV 
reactivation at our hospital, the initial three patients who 
did not receive antiviral treatment died; subsequent three 
patients who received intravenous ganciclovir in the dose 
of 5 mg/kg twice a day survived. One patient who started 
on ganciclovir left the hospital against medical advice. The 
improvement seen in some patients in a few other studies 
who received ganciclovir could also be due to the self-
limiting nature of CMV disease and therefore can't alone be 
attributed to antivirals with certainty[4,15].
  The current report of seven cases with positive 
CMV serology within day one of ICU admission adds 
a few questions to the issue of CMV reactivation in 
immunocompetent patients.  Given the significant impact 
of critical illness, limited current diagnostic options, the 
paucity of clinical data supporting a possible pathogenic role 
for CMV and the increasing dilemma over starting specific 
antivirals, there is a strong rationale for a large, prospective, 
randomised controlled trial to resolve such an important 
issue for our critically ill patients.
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